PSTV — PLUS THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1095981 ·
Last close
$3.87
Market Cap
$26.64M
52W High
$7.30
52W Low
$3.55
ADV30
175,979
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -5,742,000 | -5,713,000 | 16,325,000 | 4,256,000 | 12,329,000 |
| Sep 2025 | 0 | — | -4,482,000 | -4,423,000 | 18,670,000 | 13,289,000 | 13,616,000 |
| Jun 2025 | 0 | — | -1,538,000 | 5,151,000 | 10,350,000 | 2,233,000 | 7,316,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,841,000
Investing CF
$-12,945,000
Financing CF
$26,941,000
CapEx
$-882,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-31.55
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-522,811,000
Inventory
—
Receivables
$1,350,000
ST Investments
$12,092,000
EBIT TTM
$-8,853,000
Pretax Income TTM
$-11,931,000
Interest Exp TTM
$3,078,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,182,000
EBITDA
$-18,486,000
Free Cash Flow
$-15,108,250
Enterprise Value
$10,734,337
Total Cash
$15,114,000
Total Debt
$725,000
Shares Out
6,883,897
Trailing EPS
$21.56
Book Value
$1.74
ROE
—
ROA
-73.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,298,000 | -22,386,000 | 16,325,000 | 12,329,000 | — | -20,775,000 |
| Dec 2024 | 0 | -14,695,000 | -12,978,000 | 6,633,000 | 15,582,000 | — | -10,554,000 |
| Dec 2023 | 0 | -13,321,000 | -13,316,000 | 11,388,000 | 12,736,000 | — | -12,851,000 |
| Dec 2022 | 0 | -19,712,000 | -20,275,000 | 23,867,000 | 17,422,000 | — | -12,972,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BEAT | HeartBeam, Inc. | $27.79M | $0.50 | — |
| RDGL | VIVOS INC | $28.35M | $0.06 | — |
| PETV | PetVivo Holdings, Inc. | $24.81M | $0.66 | — |
| GTHP | GUIDED THERAPEUTICS INC | $28.96M | $0.30 | — |
| PLSM | Pulsenmore Ltd. | $23.74M | $3.65 | — |
News headlines (Yahoo Finance, 1h cache)
Cerenome Launches as an Integrated CNS Oncology Company
2026-07-31 12:30 · Yahoo
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
2026-07-28 11:30 · Yahoo
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
2026-07-21 11:30 · Yahoo
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
2026-07-16 11:30 · Yahoo
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
2026-07-14 11:30 · Yahoo
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
2026-06-30 16:55 · Yahoo
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)
2026-06-30 12:49 · Yahoo
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
2026-06-25 11:30 · Yahoo
Plus Therapeutics to Provide Business Update Call on June 30, 2026
2026-06-23 11:30 · Yahoo
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
2026-06-04 16:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.